Scarica l'app Stockscreener
3.31
1.22%
0.04
Dopo l'orario di chiusura:
3.25
-0.06
-1.81%
Precedente Chiudi:
$3.27
Aprire:
$3.54
Volume 24 ore:
224.30K
Relative Volume:
0.86
Capitalizzazione di mercato:
$222.24M
Reddito:
$7.69M
Utile/perdita netta:
$-17.65M
Rapporto P/E:
-8.8432
EPS:
-0.3743
Flusso di cassa netto:
$-15.72M
1 W Prestazione:
-10.30%
1M Prestazione:
-18.67%
6M Prestazione:
+12.97%
1 anno Prestazione:
+38.49%
Intervallo 1D:
$3.20
$3.5519
Intervallo di 1 settimana:
$3.20
$3.6921
Portata 52W:
$1.30
$4.85
Adagene Inc Adr Stock (ADAG) Company Profile
Compare ADAG vs VRTX, REGN, ARGX, MRNA, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ADAG
Adagene Inc Adr
|
3.31 | 219.56M | 7.69M | -17.65M | -15.72M | -0.3743 |
VRTX
Vertex Pharmaceuticals Inc
|
514.56 | 132.08B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
793.26 | 83.15B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
984.04 | 62.71B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
136.62 | 54.14B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
203.35 | 44.51B | 742.00K | -1.37B | -1.07B | -7.0731 |
Adagene Inc Adr Stock (ADAG) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-11-24 | Iniziato | Guggenheim | Buy |
| 2025-08-06 | Iniziato | Leerink Partners | Outperform |
| 2025-01-31 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2021-06-25 | Iniziato | China Renaissance | Buy |
| 2021-03-08 | Iniziato | Goldman | Buy |
| 2021-03-08 | Iniziato | Jefferies | Buy |
| 2021-03-08 | Iniziato | Morgan Stanley | Overweight |
Mostra tutto
Adagene Inc Adr Borsa (ADAG) Ultime notizie
Adagene, Third Arc Bio expand partnership with first lead selection - Investing.com
Adagene Announces that Third Arc Bio Has Selected First Lead Candidate under Amended Strategic Collaboration for Development of Masked CD3 T Cell Engagers Utilizing SAFEbody® Technology - The Manila Times
Cancer partner will fund new trials in Adagene (ADAG) collaboration - Stock Titan
A drug partnership picks its first lead candidate. Adagene's partner will fund clinical testing. - Stock Titan
Adagene Secures Milestone Payments in Exelixis SAFEbody ADC Collaboration - TipRanks
Cancer drug milestone brings new cash to Adagene (NASDAQ: ADAG) - Stock Titan
A cancer-drug milestone brings Adagene a $2 million payment - Stock Titan
Adagene Stock Price Forecast. Should You Buy ADAG? - StockInvest.us
Adagene Announces Clinical Collaboration with Incyte to Evaluate Muzastotug (ADG126) in Combination with Incyte’s TGFßR2xPD-1 Bispecific Antibody (INCA33890) in Patients with Microsatellite Stable Colorectal Cancer (MSS CRC) - Barchart.com
Adagene (NASDAQ: ADAG) officer to sell 131K ADS to cover option taxes - Stock Titan
Adagene to Participate in Three Upcoming Investor Conferences - GlobeNewswire
Adagene (NASDAQ: ADAG) officer plans August ADS sell-to-cover - Stock Titan
Adagene (ADAG): WuXi PharmaTech and WuXi AppTec disclose 3.5% beneficial stake - Stock Titan
Adagene Inc. (Nasdaq: ADAG) boosts cash to US$127.9M and updates H1 2026 results - Stock Titan
Adagene Reports Six Months 2026 Financial Results and Provides Corporate Updates - Yahoo Finance
Adagene’s Cancer Trial Results Expected in 1H 2027 - Stock Titan
Adagene (NASDAQ:ADAG) CEO Peter Luo Acquires 22,966 Shares - MarketBeat
Exome Asset Management LLC Decreases Holdings in Adagene Inc. Sponsored ADR $ADAG - MarketBeat
Adagene Inc. Sponsored ADR (NASDAQ:ADAG) Receives Consensus Rating of "Buy" from Analysts - MarketBeat
Adagene (ADAG) H.C. Wainwright 26th Annual Global Investment Conference 2024 summary - Quartr
Guggenheim reiterates Adagene stock Buy rating on competitor shift - Investing.com
ADAG Stock Price, Quote & Chart - ChartMill
Adagene (ADAG) Stifel 2026 Targeted Oncology Virtual Forum Summary - Quartr
Adagene Discloses Preliminary US$127.9 Million Cash Balance as of June 30, 2026 - The Globe and Mail
Adagene (ADAG) reports preliminary US$127.9M cash balance in June 2026 6-K - Stock Titan
ADAG - Finviz
Adagene, Inc. Sponsored ADR Actuals & Estimates (NASDAQ:ADAG) - TradingView
Adagene (ADAG) upgraded to buy: Here's what you should know - MSN
Adagene (NASDAQ: ADAG) Schedule 13D/A details Luo group and trust stakes - Stock Titan
Adagene (ADAG) Upgraded to Buy: Here's What You Should Know - Yahoo Finance
Guggenheim raises Adagene stock price target on cancer drug data - Investing.com
Are medical stocks lagging Adagene (ADAG) this year? - MSN
Are Medical Stocks Lagging Adagene (ADAG) This Year? - Yahoo Finance
Adagene spotlights ADG126 strategy as masked CTLA-4 trial advances in colorectal cancer - MSN
Adagene Inc. (ADAG) Presses Lower: Support Test in Sight After 1.88% DeclineTriple EMA - dars.gov.et
Adagene Spotlights ADG126 Strategy as Masked CTLA-4 Trial Advances in Colorectal Cancer - sharewise.com
WuXi entities report 3.49M-share stake in Adagene (NASDAQ: ADAG) - Stock Titan
Adagene Inc. to Participate in Stifel Annual Virtual Oncology Event and Jefferies Global Healthcare Conference - Quiver Quantitative
Adagene to Participate in Two Upcoming Investor Conferences - marketscreener.com
Janus Henderson (ADAG) reports 6.67M ADRs, 10.1% stake (04/30/2026) - Stock Titan
Analysts Offer Insights on Healthcare Companies: Adagene (ADAG) and Summit Therapeutics (SMMT) - The Globe and Mail
Adagene announces pricing of $70M public offering of ADS - MSN
Adagene Inc. Sponsored ADR (NASDAQ:ADAG) Sees Large Increase in Short Interest - MarketBeat
Adagene and Incyte Partner to Develop Colorectal Cancer Therapy - HarianBasis.co
Qinghai Zhao Net Worth (2026) - GuruFocus
Adagene reports trial data for cancer drug muzastotug combos By Investing.com - Investing.com South Africa
Adagene reports trial data for cancer drug muzastotug combos - Investing.com
Experimental Adagene drug lifts liver cancer response to 66.7% - Stock Titan
Adagene (NASDAQ: ADAG) shows strong AACR 2026 data for muzastotug combo therapies - Stock Titan
Adagene Presents Two Posters at AACR 2026 with New Data - GlobeNewswire
Adagene Looks Attractive With ADG126 And Validating Partnerships (NASDAQ:ADAG) - Seeking Alpha
Adagene Inc Adr Azioni (ADAG) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.04%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):